share_log

藥明康德：於2023年第四季度 2019年A股激勵計劃調整後 首次授予第三個行權期 授出的部分股票期權行權

WUXI APPTEC: EXERCISE OF PART OF THE SHARE OPTIONS GRANTED UNDER THE ADJUSTED INITIAL GRANT OF THE 2019 A SHARE INCENTIVE PLAN FOR THE THIRD VESTING PERIOD DURING THE FOURTH QUARTER OF 2023

香港交易所 ·  Jan 2 07:25
Summary by Moomoo AI
药明康德於2023年第四季度完成2019年A股激勵計劃第三個行權期的股票期權行權。該行權期涉及253名激勵對象，包括高層至基層管理及技術人員，共行權1,690,933股。此次行權數量佔可行權總數的73.36%，並以公司定向發行新A股普通股為來源。完成行權後，公司股權結構出現變動，有限售條件的A股減少24,357股，無限售條件的A股增加213,405股，而H股數量保持不變。本次股權變動不影響公司的實際控制人。药明康德於2024年1月2日由董事長李革博士發布公告，確認了上述信息。
药明康德於2023年第四季度完成2019年A股激勵計劃第三個行權期的股票期權行權。該行權期涉及253名激勵對象，包括高層至基層管理及技術人員，共行權1,690,933股。此次行權數量佔可行權總數的73.36%，並以公司定向發行新A股普通股為來源。完成行權後，公司股權結構出現變動，有限售條件的A股減少24,357股，無限售條件的A股增加213,405股，而H股數量保持不變。本次股權變動不影響公司的實際控制人。药明康德於2024年1月2日由董事長李革博士發布公告，確認了上述信息。
In the fourth quarter of 2023, Ming Kund completed a stock option exercise on the third stock option under the 2019 A Share Incentive Scheme. THE OPTIONS INVOLVED 253 INCENTIVES, INCLUDING SENIOR TO JUNIOR MANAGEMENT AND TECHNICAL PERSONNEL, WITH A TOTAL OF 1,690,933 SHARES. This number of subordinates represents 73.36% of the total number of options available and is derived from the Company's intended issuance of new A Shares Ordinary Shares. Following the completion of the exercise, the Company's shareholding structure changed, with a decrease of 24,357 shares of A shares under limited conditions, an increase of 213,405 shares of A shares under unlimited sale conditions, and the number of H shares remained unchanged. This change in equity does not affect the actual controller of the company. Ming Kang Pharmaceuticals issued a notice on January 2, 2024 by Chairman Dr. Li Geng confirming the above information.
In the fourth quarter of 2023, Ming Kund completed a stock option exercise on the third stock option under the 2019 A Share Incentive Scheme. THE OPTIONS INVOLVED 253 INCENTIVES, INCLUDING SENIOR TO JUNIOR MANAGEMENT AND TECHNICAL PERSONNEL, WITH A TOTAL OF 1,690,933 SHARES. This number of subordinates represents 73.36% of the total number of options available and is derived from the Company's intended issuance of new A Shares Ordinary Shares. Following the completion of the exercise, the Company's shareholding structure changed, with a decrease of 24,357 shares of A shares under limited conditions, an increase of 213,405 shares of A shares under unlimited sale conditions, and the number of H shares remained unchanged. This change in equity does not affect the actual controller of the company. Ming Kang Pharmaceuticals issued a notice on January 2, 2024 by Chairman Dr. Li Geng confirming the above information.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more